Starpharma’s drug leads to 100% survival

Company News

by Jessica Amir

A Starpharma Holdings Limited (ASX:SPL) product has significantly outperformed a major cancer drug in anti-tumour activity and increased survival in human colon cancer.

The medical company’s outperforming drug, DEP irinotecan is its dendrimer version of the major cancer drug, Camptosar (irinotecan).

In Starpharma’s studies a single treatment administrated on days 1, 8 and 15 showed better results on all cancer models tests, when compared to irinotecan.

Meantime, on its colon cancer models, Starpharma’s product resulted in complete tumor regression and 100 per cent survival.

On the back of the stellar result, Starpharma says it will be expediting its development and scaling up the drug for further pre-clinical studies, prior to clinical trials.

Shares in Starpharma Holdings Limited (ASX:SPL) are trading 2.94 per cent higher to 70 cents. 

Jessica Amir

Finance News Network
Jessica joined FNN in January 2017 after having worked in financial advising for seven years and in TV journalism for seven years, specialising in finance, equities and analysis. She has interviewed former Prime Ministers of Australia, Tony Abbott, Julia Gillard and Kevin Rudd and ex Treasurer Jo Hockey. Jessica has worked as a journalist with Sky News Business, ABC 1, ABC's The Business, ABC24 and has also been a regional Channel 7 and 9 TV reporter with Prime7 and Win News.